This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haraldseth, O. Articles by Unsgard, G. Search for Related Content PubMed PubMed Citation Articles by Haraldseth, O. Articles by Unsgard, G.

Stroke, Vol 22, 1188-1192, Copyright © 1991 by American Heart Association

ARTICLES

Quicker metabolic recovery after forebrain ischemia in rats treated with the antioxidant U74006F

O Haraldseth, T Gronas and G Unsgard
Department of Pharmacology and Toxicology, University of Trondheim, Norway.

We used phosphorus-31 nuclear magnetic resonance spectroscopy in a rat model of 10 minutes' severe incomplete forebrain ischemia (two-vessel occlusion with hypotension) to study the effects of preischemic and postischemic treatment with 3 mg/kg i.v. U74006F on the recovery of high-energy phosphates and intracellular pH during early reperfusion. The mean +/- SD time to 85% recovery of phosphocreatine was 14.1 +/- 8.4 minutes in the control group (n = 10) compared with 6.6 +/- 3.5 minutes (p less than 0.05) in the preischemic (n = 8) and 4.2 +/- 1.0 minutes (p less than 0.001) in the postischemic (n = 11) treatment groups. The mean +/- SD time to 80% recovery of adenosine triphosphate was 15.4 +/- 8.5 minutes in the control group compared with 6.3 +/- 1.8 (p less than 0.005) and 5.4 +/- 2.8 (p less than 0.001) minutes in the preischemic and postischemic treatment groups, respectively. There were no differences in intracellular pH between the control and either of the treatment groups. We conclude that U74006F led to quicker recovery of high-energy phosphates during early reperfusion, and this beneficial effect was also seen with postischemic treatment.

This article has been cited by other articles:

				R. J. Kavanagh and P. C. A. Kam Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection Br. J. Anaesth., January 1, 2001; 86(1): 110 - 119. [Abstract] [Full Text] [PDF]

				R. F. Villa and A. Gorini Pharmacology of Lazaroids and Brain Energy Metabolism: A Review Pharmacol. Rev., March 1, 1997; 49(1): 99 - 136. [Abstract] [Full Text] [PDF]

				H. Kim, R. C. Koehler, P. D. Hurn, E. D. Hall, and R. J. Traystman Amelioration of Impaired Cerebral Metabolism After Severe Acidotic Ischemia by Tirilazad Posttreatment in Dogs Stroke, January 1, 1996; 27(1): 114 - 121. [Abstract] [Full Text]

				T. B. Muller, O. Haraldseth, R. A. Jones, G. Sebastiani, C. F. Lindboe, G. Unsgard, and A. N. Oksendal Perfusion and Diffusion-Weighted MR Imaging for In Vivo Evaluation of Treatment With U74389G in a Rat Stroke Model Stroke, August 1, 1995; 26(8): 1453 - 1458. [Abstract] [Full Text]

				A. Olah, A. C. Cernaianu, T. Gaprindashvili, J. H. Cilley JR, M. M. Neuwirth, N. Ansari, and A. J. DelRossi Improvement of Spinal Cord Electrical Activity with Lazaroid (U74006F) During Operations on the Thoracic Aorta: Evaluation of a Novel Lipid Peroxidation Inhibitor Vascular and Endovascular Surgery, July 1, 1994; 28(6): 377 - 381. [Abstract] [PDF]